Abeona Therapeutics Stock Price - ABEO

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Abeona Therapeutics Inc ABEO NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 2.32 0.00 0.00 0.00 2.32 08:59:59
Bid Price Ask Price Spread Spread % News
2.25 2.50 0.25 10.0% - -
Stock Trades Traded Volume Average Volume 52 Week Range
1 2 382,612 1.46 - 9.55
Last Trade Time Type Quantity Stock Price Currency
09:07:03 2 $ 2.26 USD

Abeona Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 114.41M 49.32M $ -56.67M -1.24 - 47.12M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 1.00 4.50%

more financials information »

Abeona Therapeutics News

Loading Messages....

Latest ABEO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ABEO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.672.672.212.33245,396-0.35-13.11%
1 Month2.162.782.1152.45270,2960.167.41%
3 Months1.913.511.462.781,030,7560.4121.47%
6 Months7.417.561.463.35829,413-5.09-68.69%
1 Year8.189.551.464.81653,227-5.86-71.64%
3 Years7.3022.751.4610.87694,905-4.98-68.22%
5 Years6.6122.751.4610.26531,074-4.29-64.9%

Abeona Therapeutics Description

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases.


Your Recent History
NASDAQ
ABEO
Abeona The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.